MedTrace Logo

Extracorporeal Life Support and Modification of Hemostasis

NCT04912336 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2024-07-30

No results posted yet for this study

Summary

To evaluate change in coagulation tests during a 48-h period after initiation VV-ECMO and VA-ECMO.

(ECMO= Extra Corporeal Membrane Oxygenator) Assessment of bleeding during Veno-Venous Extracoporeal Membrane Oxygenator (VV-ECMO) and Veno-Arterial Extracoporeal Membrane Oxygenator (VA-ECMO).

Conditions

  • Bleeding Disorder
  • Extra Corporeal Life Support
  • Thrombosis

Interventions

DIAGNOSTIC_TEST

Standard coagulation profile

prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), the fibrinogen level, plateletcount

DIAGNOSTIC_TEST

Specific coagulation tests

AT III, anti Xa, ACT, ROTEM

OTHER

Bleeding Scores

Global Utilization of Streptokinase and Tpa for Occluded arteries definition of bleeding (GUSTO) AND Bleeding Academic Research Consortium Definition for Bleeding (BARC)

Sponsors & Collaborators

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Harlinde Peperstraete, MD · University Hospital, Ghent

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-28
Primary Completion
2023-01-16
Completion
2024-04-30

Countries

  • Belgium
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04912336 on ClinicalTrials.gov